Evidence map›Paper›PMID 27979915›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.

Jana Portnow, Timothy W Synold, Behnam Badie, Revathiswari Tirughana, Simon F Lacey, Massimo D'Apuzzo, Marianne Z Metz, Joseph Najbauer, Victoria Bedell, Tien Vo and 4 more

Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The effect of an adenosine AFluids and barriers of the CNS · 2018
    Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jana PortnowDepartment of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California. jportow@coh.org.
Timothy W SynoldDepartment of Cancer Biology, City of Hope, Duarte, California.
Behnam BadieDivision of Neurosurgery, City of Hope, Duarte, California.
Revathiswari TirughanaDepartment of Developmental & Stem Cell Biology, City of Hope, Duarte, California.
Simon F LaceyClinical Immunobiology Correlative Studies Laboratory, City of Hope, Duarte, California.
Massimo D'ApuzzoDepartment of Pathology, City of Hope, Duarte, California.
Marianne Z MetzDepartment of Developmental & Stem Cell Biology, City of Hope, Duarte, California.
Joseph NajbauerDepartment of Developmental & Stem Cell Biology, City of Hope, Duarte, California.
Victoria BedellCytogenetics Laboratory, City of Hope, Duarte, California.
Tien VoDepartment of Developmental & Stem Cell Biology, City of Hope, Duarte, California.
Margarita GutovaDepartment of Developmental & Stem Cell Biology, City of Hope, Duarte, California.
Paul FrankelDivision of Biostatistics, City of Hope, Duarte, California.
Mike ChenDivision of Neurosurgery, City of Hope, Duarte, California.
Karen S AboodyDivision of Neurosurgery, City of Hope, Duarte, California.
City of Hope · USCity Of Hope National Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat GliomasR21CA137639 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ABOODY, KAREN S, PORTNOW, JANA · 2009 to 2010
$730k
Phase 1 Study of Neural Stem Cells & 5-FC/Leucovorin for the Treatment of Recurrent High Grade GliomasR01FD004816 · FDA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ABOODY, KAREN S, PORTNOW, JANA · 2014 to 2016
$595k
FDA HHS R01 FD004816NCI NIH HHS P30 CA033572NCI NIH HHS R21 CA137639
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic TherapyAdolescentAdultCytosine DeaminaseFemaleFlucytosineFluorouracilGenetic VectorsGene Transfer TechniquesGliomaHumansMaleMiddle AgedNeoplasm GradingNeural Stem CellsCytosine DeaminaseFlucytosineFluorouracil

Identifiers

PMID27979915
PMCPMC8843778
OpenAlexW2561872017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.